Managing acute renal failure in patients with acute decompensated heart failure: The cardiorenal syndrome

Current Heart Failure Reports

Volumn 6, Issue 3, 2009, Pages 176-181

  Shah, Ravi V ^a   Givertz, Michael M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; CREATININE; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; NESIRITIDE; NITROPRUSSIDE SODIUM; ROLOFYLLINE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; CARDIORENAL SYNDROME; CENTRAL VENOUS PRESSURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIURESIS; DRUG DOSE ESCALATION; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART VENTRICLE OVERLOAD; HEMODYNAMICS; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REVIEW; SIDE EFFECT; ULTRAFILTRATION; URINE VOLUME;

ACUTE KIDNEY INJURY; CARDIOTONIC AGENTS; COMORBIDITY; DIURETICS; DRUG THERAPY, COMBINATION; HEART FAILURE; HEMODYNAMICS; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, VASOPRESSIN; SYNDROME; ULTRAFILTRATION; VASODILATOR AGENTS;

EID: 69549107732     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-009-0025-5     Document Type: Review

References (55)

1. Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-e181.
2. Hillege H, Girbes AR, de Kam P, et al.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102:203-210.
3. Dries D, Exner D, Domanski M, et al.: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35:681-689.
4. Heywood J, Fonarow G, Costanzo M, et al.: High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE Database. J Card Fail 2007, 13:422-430.
5. Yancy C, Lopatin M, Stevenson LW, et al.: Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006, 47:76-84.
6. Fonarow G, Adams KF, Abraham W, et al.: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572-580.
7. Fillipatos G, Rossi J, Lloyd-Jones D, et al.: Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail 2007, 13:360-364.
8. Goldberg R, Ismailov R, Patlolla V, et al.: Therapies for acute heart failure in patients with reduced kidney function: A community-based perspective. Am J Kidney Dis 2008, 51:594-602.
9. Smith G, Vaccarino V, Kosiborod M, et al.: Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003, 9:13-25.
10. Gottlieb S, Abraham W, Butler J, et al.: The prognostic importance of different definitions of worsening renal failure in congestive heart failure. J Card Fail 2002, 8:136-141.
11. Logeart D, Tabet J-Y, Hittinger L et al.: Transient worsening of renal function during hospitalization for acute heart failure alters outcomes. Int J Cardiol 2008, 127:228-232.
12. Forman D, Butler J, Wang Y, et al.: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004, 43:61-67.
13. Butler J, Forman D, Abraham W, et al.: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331-338.
14. Ronco C, Haapio M, House A, et al.: Cardiorenal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
15. Nohria A, Hasselblad V, Stebbins A, et al.: Cardiorenal interactions insights from the ESCAPE trial. J Am Coll Cardiol 2008, 51:1268-1274.
16. Damman K, Navis G, Smilde T, et al.: Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007, 9:872-878.
17. Mullens W, Abrahams Z, Francis G, et al.: Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009, 53:589-596.
18. Mullens W, Abrahams Z, Skouri H, et al.: Elevated intraabdominal pressure in acute decompensated heart failure: A potential contributor to worsening renal function? J Am Coll Cardiol 2008, 51:300-306.
19. Costanzo M, Johannes R, Pine M, et al.: The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 2007, 154:267-277.
20. Mullens W, Abrahams Z, Francis G, et al.: Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008, 52:200-207.
21. Sackner-Bernstein J, Kowalski M, Fox M, et al.: Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005, 293:1900-1905.
22. Sackner-Bernstein J, Skopicki H, Aaronson K: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
23. McCullough P: Contrast-induced acute kidney injury. J Am Coll Cardiol 2008, 51:1419-1428.
24. Peacock WF, Costanzo M, De Marco T, et al.: Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: Insights from the ADHERE registry. Cardiology 2009, 113:12-19.
25. Bongartz L, Jan Cramer M, Doevendans P, et al.: The severe cardiorenal syndrome: "Guyton revisited". Eur Heart J 2005, 26:11-17.
26. Kelly K: Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol 2003, 14:1549-1558.
27. Jie K, Verhaar M, Jan Cramer M, et al.: Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006, 291:932-944.
28. Palazzuoli A, Silverberg D, Iovine F, et al.: Effects of erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007, 154:645e9-645e15.
29. Brater D: Diuretic therapy. N Engl J Med 1998, 339:387-395.
30. Vasko M, Cartwright D, Knochel J, et al.: Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985, 102:314-318.
31. Abdallah J, Schrier R, Edelstein C, et al.: Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: Role of aldosterone. J Am Soc Nephrol 2001, 12:1335-1341.
32. Lahav M, Regev A, Ra'anani P, et al.: Intermittent administration of furosemide versus continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992, 102:725-731.
33. Dormans T, van Meyel JJ, Gerlag P, et al.: Diuretic efficacy of high dose furosemide in severe heart failure: Bolus injection versus continuous infusion. J Am Coll Cardiol 1996, 28:376-382.
34. Salvador DR, Rey NR, Ramos GC, Punzalan FE: Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005, 20:CD003178.
35. Howard P, Dunn M: Aggressive diuresis for severe heart failure in the elderly. Chest 2001, 119:807-810.
36. Heart Failure Network: Available at http://www.hfnetwork.org. Accessed December 3, 2008.
37. Allen L, Rogers J, WarnicT J, et al.: High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. J Card Fail 2008, 14:661-669.
38. Elkayam U, Ng, T, Hatamizadeh P, et al.: Renal vasodilatory action of dopamine in patients with heart failure: Magnitude of effect and site of action. Circulation 2008, 117:200-205.
39. Ungar A, Fumagalli S, Marini M, et al.: Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit Care Med 2004, 32:1126-1129.
40. Abraham WT, Adams KF, Fonarow GC, et al.: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46:57-64.
41. Iglesias J, DePalma L, Hom D, et al.: Predictors of mortality in adult patients with congestive heart failure receiving nesiritide-retrospective analysis showing a potential adverse interaction between neseritide [sic] and acute renal dysfunction. Nephrol Dial Transplant 2008, 23:144-153.
42. Witteles R, Kao D, Christopherson D, et al.: Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction. J Am Coll Cardiol 2007, 50:1835-1840.
43. Yancy C, Krum H, Massie B, et al.: Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: Results of the second follow-up serial infusions of nesiritide (FUSION-II) trial. Circ Heart Fail 2008, 1:9-16.
44. Riter H, Redfield M, Burnett J, et al.: Nonhypotensive lowdose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 2006, 47:2334-2335.
45. Armstrong P, Rouleau J: A Canadian context for the acute study of clinical effectiveness of nesiritide and decompensated heart failure (ASCEND-HF) trial. Can J Cardiol 2008, 24:30B-32B.
46. Wertman B, Gura V, Schwarz E: Ultrafiltration for the management of acute decompensated heart failure. J Card Fail 2008, 14:754-759.
47. Agostoni P, Marenzi G, Lauri G, et al.: Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: Failure of furosemide to provide the same result. Am J Med 1994, 96:191-199.
48. Costanzo M, Guglin M, Saltzberg M, et al.: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49:675-683.
49. Konstam M, Gheorghiade M, Burnett J, et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA 2007, 297:1319-1331.
50. Goldsmith S: Treatment options for hyponatremia in heart failure. Heart Fail Rev 2009, 14:87-88.
51. Kriz W: AdenoTine and ATP: traffic regulators in the kidney. J Clin Invest 2004, 114:611-613.
52. Vallon V, Muhlbauer B, Osswald H: Adenosine and kidney function. Physiol Rev 2006, 86:901-940.
53. Givertz M, Massie B, Fields T, et al.: The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007, 50:1551-1560.
54. Cotter G, Dittrich A, Weatherley B, et al.: The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008, 14:631-640.
55. Merck.com: Rolofylline did not demonstrate efficacy for acute heart failure in clinical trial. Available at http://www.merck.com/newsroom/ press_releases/research_and_development/2009_0605.html. Accessed June 19, 2009.